---
title: "Compugen Ltd. (CGEN.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/CGEN.US.md"
symbol: "CGEN.US"
name: "Compugen Ltd."
industry: "Biotechnology"
datetime: "2026-05-20T09:31:42.699Z"
locales:
  - [en](https://longbridge.com/en/quote/CGEN.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/CGEN.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/CGEN.US.md)
---

# Compugen Ltd. (CGEN.US)

## Company Overview

Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company’s pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti- PD-1/TIGIT bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer. Its preclinical therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [cgen.com](https://cgen.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:13.000Z

**Overall: B (0.27)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 46 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 163.35% |  |
| Net Profit YoY | 346.41% |  |
| P/B Ratio | 2.71 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 258132766.71 |  |
| Revenue | 72656000.00 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 45.72% | A |
| Profit Margin | 47.97% | A |
| Gross Margin | 16.18% | D |
| Revenue YoY | 163.35% | A |
| Net Profit YoY | 346.41% | A |
| Total Assets YoY | 26.35% | A |
| Net Assets YoY | 66.97% | A |
| Cash Flow Margin | 0.00% | D |
| OCF YoY | 163.35% | A |
| Turnover | 0.56 | C |
| Gearing Ratio | 34.63% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Compugen Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "163.35%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "346.41%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.71",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "258132766.71",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "72656000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "45.72%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "47.97%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "16.18%",
          "rating": "D"
        },
        {
          "name": "Revenue YoY",
          "value": "163.35%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "346.41%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "26.35%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "66.97%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "163.35%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.56",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "34.63%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 7.41 | 21/386 | 7.65 | 6.63 | 5.66 |
| PB | 2.71 | 241/386 | 3.44 | 2.77 | 2.49 |
| PS (TTM) | 3.55 | 84/386 | 21.54 | 6.04 | 3.77 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-19T04:00:00.000Z

Total Analysts: **5**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 5 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 2.73 |
| Highest Target | 13.00 |
| Lowest Target | 4.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/CGEN.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/CGEN.US/norm.md)
- [Related News](https://longbridge.com/en/quote/CGEN.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/CGEN.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**